Anti-Cancer Drugs · 2023 · 29 citations · 45 references
MedicineCancer BiologyMolecular BiologyDna RepairEpigeneticsMolecular OncologyCancer EpigeneticsCancer Stem CellsChromatinEpigenetic Regulation In CancerHistone ModificationsHistone ProteinsAnticancer ActivityCancer Stem Cell EpigeneticsEpigenetic RegulationHistone Demethylase InhibitionHistone DemethylasesHistone DemethylationHistone H3 Lysine 4 MethylationReplicative Immortality
Histone lysine demethylase 4 (KDM4) is an epigenetic regulator that facilitates the transition between transcriptionally silent and active chromatin states by catalyzing the removal of methyl groups on histones H3K9, H3K36, and H1.4K26. KDM4 overamplification or dysregulation has been reported in various cancers and has been shown to drive key processes linked to tumorigenesis, such as replicative immortality, evasion of apoptosis, metastasis, DNA repair deficiency, and genomic instability. KDM4 also plays a role in epigenetic regulation of cancer stem cell renewal and has been linked to more aggressive disease and poorer clinical outcomes. The KDM4 family is composed of four main isoforms (KDM4A-D) that demonstrate functional redundancy and cross-activity; thus, selective inhibition of one isoform appears to be ineffective and pan-inhibition targeting multiple KDM4 isoforms is required. Here, we describe TACH101, a novel, small-molecule pan-inhibitor of KDM4 that selectively targets KDM4A-D with no effect on other KDM families. TACH101 demonstrated potent antiproliferative activity in cancer cell lines and organoid models derived from various histologies, including colorectal, esophageal, gastric, breast, pancreatic, and hematological malignancies. In vivo , potent inhibition of KDM4 led to efficient tumor growth inhibition and regression in several xenograft models. A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.
45
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Paul A. Cloos, Karl Agger, Alessio Maiolica et al. · Nature · 2006 · 749 citations
Jonghwan Kim, Andrew J. Woo, Jianlin Chu et al. · Cell · 2010 · 670 citations · Full text
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36
Robert J. Klose, Kenichi Yamane, Yangjin Bae et al. · Nature · 2006 · 620 citations
Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells
Yuin‐Han Loh, Weiwei Zhang, Xi Chen et al. · Genes & Development · 2007 · 513 citations · Full text